🇺🇸 FDA
Pipeline program

Recaticimab

IIT-I-2025-098

Approved small_molecule active

Quick answer

Recaticimab for STEMI - ST Elevation Myocardial Infarction is a Approved program (small_molecule) at The First People's Hospital of Lianyungang with 1 ClinicalTrials.gov record(s).

Program details

Company
The First People's Hospital of Lianyungang
Indication
STEMI - ST Elevation Myocardial Infarction
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials